Published on: Oct 27, 2016 at PR Newswire

Daiichi Sankyo Presents Late-Breaking Phase 1 Data for Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a in T-DM1 Pre-Treated Breast Cancer at the ESMO 2016 Congress

By : PR Newswire

Preliminary trials for a new antibody drug shows patients tolerated the treatment well with a 90% disease control rate for gastric cancer patients.

Read More
SHARE